Abstract
Successful treatment of solid cancers relies on complete surgical excision of the tumor either for definitive treatment or before adjuvant therapy. Radial sectioning of the resected tumor and surrounding tissue is the most common form of intra-operative and post-operative margin assessment. However, this technique samples only a tiny fraction of the available tissue and therefore may result in incomplete excision of the tumor, increasing the risk of recurrence and distant metastasis and decreasing survival. Repeat procedures, chemotherapy, and other resulting treatments pose significant morbidity, mortality, and fiscal costs for our healthcare system. Mohs Micrographic Surgery (MMS) is used for the removal of basal cell and squamous cell carcinoma utilizing frozen sections for real-time margin assessment while assessing 100% of the peripheral and deep margins, resulting in a recurrence rate of less than one percent. Real-time assessment in many tumor types is constrained by tissue size and complexity and the time to process tissue and evaluate slides while a patient is under general anesthesia. In this study, we developed an artificial intelligence (AI) platform, ArcticAI, which augments the surgical workflow to improve efficiency by reducing rate-limiting steps in tissue preprocessing and histological assessment through automated mapping and orientation of tumor to the surgical specimen. Using basal cell carcinoma (BCC) as a model system, the results demonstrate that ArcticAI can provide effective grossing recommendations, accurately identify tumor on histological sections, map tumor back onto the surgical resection map, and automate pathology report generation resulting in seamless communication between the surgical pathology laboratory and surgeon. AI-augmented-surgical excision workflows may make real-time margin assessment for the excision of more complex and challenging tumor types more accessible, leading to more streamlined and accurate tumor removal while increasing healthcare delivery efficiency.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
JL is funded in part under NIH subaward of grant number P20GM104416.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Research Protection Program (IRB) of Dartmouth Hitchcock Medical Center gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The datasets presented in this article are not readily available because of participant privacy concerns. Requests to access the datasets should be directed to joshua.j.levy{at}dartmouth.edu.
